SEC Form 4 · accession 0001493152-18-006673
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Frederick Head
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
May 9, 2018
Accepted (ET)
May 11, 2018 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $0.0135 | May 9, 2018 | A | 3,000,000 | A | May 9, 2019 | May 9, 2028 | Common Stock | 3,000,000 | 5,000,000 | D |
Explanation of responses
- F1Options issued as compensation approved by the Issuer's Board of Directors.